Zhejiang Orient Gene Biotech Co., Ltd. (688298.SS)
CNY 29.1
(-2.68%)
CNY 29.1
(-2.68%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 736.58 Million CNY | -37.03% |
| 2022 | 1.33 Billion CNY | -17.83% |
| 2021 | 1.62 Billion CNY | 250.02% |
| 2020 | 463.26 Million CNY | 478.66% |
| 2019 | 80.05 Million CNY | 23.03% |
| 2018 | 65.07 Million CNY | 15.71% |
| 2017 | 56.23 Million CNY | 32.23% |
| 2016 | 42.53 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 204.66 Million CNY | -53.52% |
| 2024 Q3 | 204.43 Million CNY | 6.77% |
| 2024 Q2 | 189.16 Million CNY | -7.57% |
| 2023 Q2 | 184.01 Million CNY | 7.1% |
| 2023 FY | 838.99 Million CNY | -37.03% |
| 2023 Q1 | 171.8 Million CNY | -13.97% |
| 2023 Q3 | 196.55 Million CNY | 6.82% |
| 2023 Q4 | 440.27 Million CNY | 123.99% |
| 2022 Q2 | 480.39 Million CNY | 2.12% |
| 2022 FY | 1.33 Billion CNY | -17.83% |
| 2022 Q4 | 199.7 Million CNY | 9.82% |
| 2022 Q3 | 181.83 Million CNY | -62.15% |
| 2022 Q1 | 470.41 Million CNY | -20.6% |
| 2021 Q1 | 339.39 Million CNY | -0.55% |
| 2021 Q3 | 173.02 Million CNY | -66.51% |
| 2021 FY | 1.62 Billion CNY | 250.02% |
| 2021 Q4 | 592.44 Million CNY | 242.41% |
| 2021 Q2 | 516.68 Million CNY | 52.24% |
| 2020 Q3 | 45.89 Million CNY | -18.91% |
| 2020 Q1 | 19.5 Million CNY | -14.03% |
| 2020 FY | 463.26 Million CNY | 478.66% |
| 2020 Q4 | 341.27 Million CNY | 643.62% |
| 2020 Q2 | 56.59 Million CNY | 190.09% |
| 2019 Q3 | 19.06 Million CNY | -0.63% |
| 2019 FY | 80.05 Million CNY | 23.03% |
| 2019 Q4 | 22.69 Million CNY | 19.0% |
| 2019 Q2 | 19.19 Million CNY | 0.45% |
| 2019 Q1 | 19.1 Million CNY | 8.56% |
| 2018 Q4 | 17.6 Million CNY | 0.0% |
| 2018 FY | 65.07 Million CNY | 15.71% |
| 2017 FY | 56.23 Million CNY | 32.23% |
| 2016 FY | 42.53 Million CNY | 0.0% |